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ABSTRACT 
We report on the de novo design of a biologically active amyloidogenic 
peptide that inhibits VEGFR2 function and reduces VEGFR2 dependent tumor 
growth in mice xenografts upon intravenous administration. This peptide, 
consisting of a tandem repeat of an amyloidogenic fragment of VEGFR2, forms 
prefibrillar oligomers, protofibrils and mature fibrils, penetrates cells and 
seeds the aggregation of VEGFR2 by direct interaction. Our results therefore 
show that a short amyloidogenic protein fragment can induce the aggregation 
of a protein normally not associated to amyloidosis in a manner that 
recapitulates key biophysical and biochemical characteristics of natural 
amyloids. In addition we find that amyloid toxicity is observed only in cells that 
both express VEGFR2 and are dependent of VEGFR2 for survival. Thus rather 
than being generic, amyloid toxicity here appears to be both protein specific 
and conditional, i.e. determined by VEGFR2 loss-of-function in a biological 
context where target protein function is essential. 
 
INTRODUCTION 
Amyloid aggregation of proteins is driven by short amyloidogenic sequence 
segments within a protein chain (1, 2) that have the potential to self-assemble into -
sheet ribbons to form the characteristic cross-beta structured spine of amyloid 
structures (3, 4). It has been showed that most proteins do in fact possess such 
amyloidogenic sequence segments (5, 6). Still, only about 30 human proteins are 
known to be involved in amyloid-associated diseases (7, 8). Moreover it is still not 
clear what determines amyloid toxicity in these diseases (8, 9). Here we investigate 
whether an endogenously expressed protein that possesses amyloidogenic potential 
but aggregates neither under normal nor pathological conditions, can be induced to 
do so by seeding with a peptide consisting of an amyloidogenic fragment of its own 
sequence. The use of amyloidogenic fragment peptides is motivated by the 
observation that aggregation of disease–associated amyloidogenic proteins can be 
seeded by such peptides in vitro (10, 11) and that truncations of amyloid proteins 
have been associated with increased seeding potential in vivo (12, 13). Moreover it 
has been shown that amyloidogenic peptides and proteins are generally much more 
efficient at seeding aggregation of homotypic sequences (14-16) although examples 
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of cross seeding do exist (17-19). Indeed, seeding of protein aggregation in vitro 
appears to work universally, and fits with the structural model of aggregation as the 
addition of new strands to a growing amyloid fibril (8). This imparts sequence 
specificity to the seeding process as the incorporation of non-homologous sequences 
into the highly ordered in-register stacking of identical side chains in the fibril core is 
likely to be energetically disfavoured (13, 20, 21). The seeding concept appears to 
hold true both in cell culture and in vivo, even for non-prion aggregation-associated 
peptides and proteins, which have hence been called prionoids (22). As a target 
protein we choose VEGFR2 as the function of this protein is well characterized. To 
ensure efficient seeding we designed an amyloidogenic peptide termed vascin 
consisting of a tandem repeat of an amyloidogenic sequence segment in the VEGFR2 
signal peptide.  
We find that vascin is a bona fide amyloidogenic peptide that forms mature 
cross-beta fibrils along with prefibrillar intermediates including soluble oligomers 
and protofibrils. Moreover we find that the peptide is able to enter cells and reach 
the cytoplasmic compartment and specifically induce the aggregation of endogenous 
VEGFR2 thereby inhibiting its function in Human vein endothelial cells (HUVEC) in 
vitro and reducing VEGFR2-dependent tumor progression in vivo.   
It remains unclear what determines amyloid toxicity in amyloid diseases and 
whether cell death results from a consequence of direct amyloid toxicity (gain-of-
function) or whether it is a consequence of loss-of-function (23, 24). However, our 
detailed understanding of real amyloid disease models is often insufficient to address 
these questions directly. Indeed for many disease associated amyloidogenic proteins 
–such as the A peptide in Alzheimer disease (25) and -synuclein in Parkinson 
disease (26)- we still have insufficient understanding both of their physiological role 
as well as the cellular interactions of the amyloid conformation in disease (26, 27). 
We do however have a better understanding of the structural and biochemical 
characteristics that are common to most amyloid diseases. These features include the 
cross-beta structural organization of the spine of the amyloid fibrils formed by short 
segments of the sequence, the population of prefibrillar intermediates including 
soluble oligomers and protofibrils, and the capacity of amyloids to seed aggregation 
of the native conformation. While our artificial amyloid model recapitulates these 
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key structural and biochemical features of natural amyloids, it is also simple enough 
to investigate the relationship between protein loss-of-function and amyloid toxicity.  
Our results show that vascin amyloids are not inherently toxic but that the 
emergence of amyloid toxicity is dependent on biological context. Vascin is not toxic 
to cells that do not express VEGFR2 or to cells expressing VEGFR2 but that are not 
dependent on VEGFR2 function. However when introduced in VEGFR2 dependent 
cells we find association of vascin amyloid toxicity and VEGFR2 loss-of-function. Our 
model system therefore demonstrates that amyloidogenic protein fragments can 
induce aggregation of non amyloidogenic proteins and that under these conditions 
amyloid gain of function is a phenotypic effect resulting from cell context specific 
loss-of-function.  
 
RESULTS 
Design of vascin, an amyloidogenic peptide derived from a VEGFR2 fragment 
We analyzed the VEGFR2 receptors from mouse and human using the statistical 
thermodynamics algorithm TANGO (28) (Suppl Fig 1A). Since we envisaged testing 
the sequence ultimately in a mouse model, we opted for maximal compatibility with 
this version of the protein. Moreover, the two homologs share 84% sequence identity 
overall and 90% in the tango regions. To derive peptide sequences that are likely to 
form amyloid structure in isolation, but also have a high potential for forming soluble 
oligomers (29), we devised a strategy (30, 31) that makes use of a sequence feature 
of functional amyloids and yeast prions, which often contain several aggregation 
prone segments (APR) (32) closely connected by disordered regions (33). Hence we 
placed two ARPs in a peptide, separated by a rigid Pro-Pro linker, mimicking these 
repeat patterns. In order to maintain colloidal stability and solubility of the sequence, 
we supercharged the peptides by flanking the APRs with either negatively charged 
aspartate or positively charged arginine residues. Given the length limitations 
imposed by the efficiency of solid phase peptide synthesis, this design scheme 
imposes a length limitation on the APRs of 7 amino acids. Hence we selected 10 such 
high scoring sequences (Suppl Table 1) and generated the 38 peptide sequences 
listed in table 2, which explore both tandem repeats of the same APR as well as 
fusions of different APRs (Suppl Table 2). Peptides were screened for their ability to 
inhibit VEGF signalling in Hek293 cells transfected with mouse VEGFR2. To this end, 
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cells were treated overnight with an apparent concentration of 20 M peptide 
(assuming 100% synthesis efficiency) and ERK phosphorylation was determined 
after stimulation for 5 min with 50 ng/mL VEGF (Suppl Fig 1B). At this 
concentration, we observed inhibition only with 2 peptides (B8 and B12). The effect 
was most pronounced with the peptide B8, which was based on a tandem repeat of 
the first high scoring aggregation prone region in the sequence that derives from the 
signal peptide and has the sequence L6AVALWF12 (Supplementary Figure 2A), 
resulting in the sequence DLAVALWFDPPDLAVALWFD (pI = 3.38, M.W. = 2272.15 
Da). We termed this peptide vascin (Supplementary Figure 2B), obtained additional 
material by solid phase peptide synthesis followed by HPLC purification 
(Supplementary figure 2B), and confirmed its identity by mass spectrometry 
(observed mass: 2272.4, supplementary figure 2D). 
 
Vascin forms soluble beta-structured oligomers that mature into amyloid 
fibrils  
To determine the amyloidogenic nature of the peptide, vascin was dissolved 
to a final concentration of 300 M in 1% (w/v) ammonium bicarbonate in ddH2O. 
After 24 hours incubation Transmission Electron Microscopy (TEM) revealed typical 
amyloid fibrils of about 10 nm in width consisting of protofilaments of 4-5 nm 
(Figure 1A-D and Supplementary Figure 3). Additionally, vascin fibrils bind amyloid 
sensor dyes, including Thioflavin-T and the amyloid specific oligothiophene  h-HTAA 
(34) displaying the characteristic emission spectra of beta amyloids (Figure 1E). X-
ray diffraction of aligned bundles of vascin fibrils confirmed their cross-beta nature, 
with characteristic diffractions at 4.7 and 10.0 Å (Figure 1F). Together these data 
confirm the amyloidogenic nature of vascin. In order to follow amyloid formation 
kinetics we filtered dissolved 300 M vascin 1% (w/v) ammonium bicarbonate in 
ddH2O through a 0.2 m regenerated cellulose filter and monitored particle size 
distribution using electrospray ionisation-mass spectrometry linked to ion mobility 
spectrometry (ESI-IMS-MS)(35) (Figure 1G) and  Dynamic Light Scattering (DLS) 
(Figure 1H). At time zero, the MS showed a mixture of monomers and multimers up 
to X (Figure 1G), whereas the particle sizes visible in the DLS ranged from 5-100 nm 
(assuming linear polymer particles). After 6 h particles reached sizes over 1 m 
(Figure 1H). This indicates that the filtered vascin solution contains soluble 
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oligomeric aggregates already at time zero. The fact that no lag phase was observed 
in the DLS autocorrelation function (Supplementary Figure 4A & B) further suggests 
that these soluble oligomers are able to directly proceed to amyloid fibril formation. 
In order to probe the secondary structure of these soluble aggregates we monitored 
the same aggregation kinetics using Fourier Transform Infrared Spectroscopy (FT-
IR). The spectrum at time zero was dominated by maxima near 1630 and 1690 cm-1 
(Figure 1I), characteristic of -sheet structure. Over the following 6 h the intensity of 
these peaks increased markedly while the center of the peaks shifted gradually to 
1622 and 1692 cm-1, respectively (Figure 1I&J). These peaks were quite narrow and 
regions outside the peaks showed very little absorption, suggesting that most of the 
peptide sequence is involved in -structured hydrogen bonding. FT-IR kinetics 
therefore indicate that vascin largely adopts a -structured conformation upon 
solubilization in 1% bicarbonate and that these species mature into amyloid fibrils 
over time. Finally we measured binding to 8-Anilino-1-naphthalenesulphonic acid 
(ANS) during vascin amyloid formation (Supplementary Figure 4C), revealing high 
binding of this dye at time zero.  The latter is a typical feature of interaction-prone 
cytotoxic prefibrillar oligomers that present a high degree of solvent exposed 
hydrophobic surface (36). The binding of ANS increased over time, suggesting 
hydrophobic surfaces stay exposed upon fibril formation. Given that the above 
observations were made at 300  M peptide where the signal to noise ratio for 
biophysical characterisation is optimal, we also verified that vascin readily formed 
amyloid fibrils at the lower concentration of 30 M (Supplementary Figure 5). 
Compared to vascin a scrambled version of the peptide (Supplementary Note 1) 
formed small soluble aggregates with hydrodynamic radii smaller than 100 nm by 
Dynamic Light Scattering, DLS (Supplementary Figure 6A&B) that exhibited a non-
fibrillar morphology via TEM (Supplementary Figure 6C), and displayed marginal 
affinity for the amyloid sensor dyes with no specific emission spectrum for amyloid 
fibers (Figure 1E). Similar observation were made with  a vascin variant in which 
proline mutations were introduced to break the beta-sheet propensity of the APRs in 
vascin (Supplementary Note 2, Supplementary Figure 7). In contrast, a version of 
vascin based on the human sequence (hVascin, DLAVALWLDPPDLAVALWLD), 
containing a single mutation of Phe to Leu at position 7 of the APR, displayed similar 
amyloid formation as the original mouse sequence (Supplementary Figure 8). 
  Design of a biologically active amyloid 
  Page 8/21 
In conclusion the biophysical characterization above confirms that vascin is 
an amyloidogenic peptide that readily forms -structured soluble oligomeric 
aggregates that mature into cross- structured amyloid fibrils in a broad 
concentration range.  
 
Vascin inactivates VEGFR2 in human vein endothelial cells by inducing its 
aggregation 
As vascin is an amyloidogenic peptide derived from a VEGFR2 fragment we 
investigated whether vascin displays biological activity towards VEGFR2 in cultured 
cells. First, we monitored cellular uptake of vascin using carboxyfluorescein labelled 
vascin (CF-vascin) in human vein endothelial cells (HUVEC). We observed cellular 
uptake during the first hour of incubation as small vesicles or inclusions that 
contained diffuse homogeneous peptide (Figure 2A). Moreover, these inclusions 
were positive for the amyloid sensor dye pFTAA (Figure 2B&C), showing that the 
peptide remains in an amyloid-like conformation inside the cells. Co-staining for the 
ER protein Calnexin reveals that the peptide is on the cytoplasmic side of the ER 
(Figure 2D), where it partially overlaps with staining for ribosomes (Figure 2E). 
Proximity ligation (Duo-Link) using antibodies against VEGFR2 and the 
carboxyfluorescein-label on the peptide (Figure 2F), quantified by image analysis 
from high content microscopy demonstrated direct interaction between vascin and 
VEGFR2 (Figure 2G).  This result was further confirmed by two color direct 
stochastic optical reconstruction microscopy (dSTORM) super-resolution 
imaging(37) using 0.5µM of Alexa647 labeled vascin and Alexa568 labeled VEGFR2 
(Figure 2H&I).  
Co-immunoprecipitation of VEGFR2 from lysates of vascin-treated cells was 
performed with PEG-biotin labeled peptide again demonstrating direct interaction 
between vascin and VEGFR2 (Figure 3A). To investigate the consequences of the 
interaction between vascin and VEGFR2 on the aggregation status of the receptor, we 
determined the difference in distribution of VEGFR2 between soluble and insoluble 
lysate fractions of HUVECs treated with 20 µM of vascin. Upon vascin treatment we 
could observe a clear redistribution of full length and partially degraded VEGFR2 
towards the insoluble fraction whereas this was not the case upon treatment with 
scrambled vascin (Figure 3B). In addition, the induced insoluble VEGFR2 displays 
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partial resistance to the ionic detergent SDS, a hallmark of amyloid-like aggregation 
(Figure 3C). To confirm that vascin mediated aggregation of VEGFR2 in HUVECs 
leads to its loss function we determined the dose response curve of vascin on 
VEGFR2 autophosphorylation and ERK phosphorylation (MSD ELISA assay) after 
stimulating HUVECs for 5 min with 1.3 nM VEGF. HUVECs displayed a clear dose 
responsive inhibition by vascin with an IC50 of 6.8 +- 0.5 M for receptor 
autophosphorylation and 8.3 +- 0.4 M for ERK phosphorylation (Figure 3D&E). The 
human version of vascin did show similar inhibition, which was not observed using 
the scrambled or proline controls (Figure 3F). Using fluorescence-activated cell 
sorting (FACS) and immunofluorescence microscopy we observed a concomitant 
reduction in the surface expression of VEGFR2 in HUVECs, but not of the unrelated 
cell-surface protein CD29 (Figure 3G & Supplementary Figure 9), confirming loss of 
VEGFR2 function in HUVECs. Together these data show that vascin is internalized by 
HUVECs and reaches the cytoplasmic compartment where it directly binds to 
VEGFR2 and localizes with ribosomes, resulting in the functional inactivation 
through aggregation of VEGFR2. This effect seemed to be specific as indicated by the 
CD29 result. Moreover, we observed no effect of vascin on EGF signalling in HeLa 
cells, which do not endogenously express VEGFR2 but the functionally homologous 
EGF receptor ErbB2. Treatment of this cell line with 20 M vascin showed no 
inhibition of ERK phosphorylation in resonse to stimulation with EGF, showing that 
the effect is specific to VEGFR2 (Figure 3H). To test if known amyloidogenic proteins 
were affected by vascin, we investigated the effect of adding vascin to solutions of the 
Alzheimer -peptide 1-42 (A, Figure 3I) or the human Prion protein (PrP, Figure 3J). 
The mean lag time for spontaneous conversion of Aβ1-40 was 350 minutes whereas 
addition of preformed Aβ fibrils decreased the lag time to 130 minutes. Addition of 
B8 fibril variants did not lead to significant decrease of fibrillation lag times other 
than for B8 Scr3 where the significance level in a paired T-test was p>0,03. The mean 
lag time for spontaneous conversion of HuPrP23-231 was 1100 minutes. The 
conversion rate upon addition of preformed HuPrP90-231 fibrils was shortened to 
135 minutes whereas addition of preformed B8 fibril variants did not lead to 
significant alteration of lag time. 
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Vascin reduces VEGFR2-dependent tumor growth in mice 
To establish the effect of vascin in vivo we turned to a functional angiogenesis model 
that is sensitive to inhibition of VEGFR2 in vivo and used a subcutaneous B16 
melanoma syngenic tumor model in C57BL/6 inbred mice. Tumor growth of this line 
is strongly reduced by VEGFR-specific inhibition approaches, such as the tyrosine 
kinase inhibitor PTK 787/ZK 222584 (38), providing a sensitive phenotypic readout 
for the anticipated effect of vascin. To assess if vascin administration would be 
tolerated by C57BL/6 mice we first performed a dose-escalation study by daily tail 
vein injections in two six-week-old, inbred C57BL/6 mice, starting from 1 mg/kg to 
10 mg/kg, which corresponded to the highest stock concentration of the peptide that 
we could reach with the available material. No adverse effects to the basic 
physiological and behavioral parameters of the animals was apparent across this 
concentration range, including body weight, food and water consumption, home cage 
activity and locomotion. To test the effect of vascin on tumor growth, B16 cells were 
injected subcutaneously in the right dorsal flank of eight-week-old C57BL/6 mice. 
Starting from three days post tumor injection and until day 17, mice were treated 
daily by intravenous delivery of 10 mg/kg vascin (N=10) or scrambled vascin as the 
negative control (N=10). Another negative control group received intravenous 
delivery of the vehicle (50 mM Tris pH7.5, N=10) and the positive control group 
(N=5) received the kinase inhibitor PTK787 orally (75mg/kg). Tumor growth was 
similar in animals treated with scrambled vascin or vehicle, and markedly reduced in 
animals that received the PTK inhibitor. In the vascin treated group tumor growth 
was significantly inhibited compared to the negative controls over the entire 
experiment (ANOVA with Tukey post-hoc) and up to day 14 to a similar extent than 
the PTK treated group (Figure 4A). 
In order to exclude overall toxicity effects of vascin on tumor growth, we executed a 
short term toxicology study in which we treated groups of 5 mice daily with 10 
mg/kg of vascin (group A), scrambled (group B) or vehicle (50 mM Tris pH 7.5) for 
14 days (the same duration as the tumor growth experiment). Gross examination at 
necropsy did not reveal any macroscopic changes (Supplementary Figure 10A). 
Concerning organ weights (Supplementary Figure 10B), hematology (Supplementary 
Figure 10C) and clinical chemistry (Supplementary Figure 10D), no statistically 
significant differences were observed among groups. Also no significant variations 
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were observed among the experimental groups in terms of lesion spectrum, 
frequency and severity. In addition, we examined brain sections from all the animals 
for amyloid deposition and associated astrogliosis. Thioflavin-S-positive deposits in 
the neuroparenchyma were not detected (Supplementary Figure 11 A, B & C) and co-
staining with GFAP (glial fibrillary acidic protein) did not show any morphological 
evidence of astrogliosis, in sharp contrast to the positive control (Supplementary 
Figure 11D), for which we employed a transgenic Alzheimer disease mouse model 
that has marked amyloid deposition throughout the cortex and hippocampus (39).  
 In order to demonstrate the arrival and presence of B8-FITC at the tumor site, 
two groups of tumor-bearing mice were injected i.v. with B8-FITC or vehicle (PBS, 
negative control) and imaged with whole-body fluorescence imaging. Because the 
melanin-expression by the tumors strongly absorbs light hampering the in vivo 
detection of fluorescence, tumors were isolated and imaged ex vivo. The resulting 
fluorescence images showed strong green fluorescence emission for tumors isolated 
from B8-FITC-injected mice, whereas no fluorescence could be detected from tumors 
isolated from vehicle-injected control mice (Supplementary Figure 12A), supporting 
the presence of B8-FITC at the tumor site based on macroscopic FITC-fluorescence 
measurements.  To further verify the presence of B8-FITC inside the tumor tissue 
with microscopic resolution, we additionally examined the presence of fluorescently 
tagged B8 with fibered confocal fluorescence microscopy (FCFM) on tumor samples 
from the same mice.  Inserting the fibre-optical probe inside the tumor tissue sample 
of vehicle-injected control mice did not show any fluorescence signal, whereas the 
tumor samples of B8-FITC-injected mice were clearly positive for green fluorescence 
(Supplementary Figure 12 B). To quantify B8 in B16 tumors, the specific light 
absorption by melanomas was calibrated through the addition of different known 
quantities of B8-FITC to series of tumor tissue dilutions and compared to a standard 
curve of fluorescence intensity for a dilution series of pure B8-FITC.  Both were 
found to be linear in a large concentration range and for two different fluorescence 
imaging modalities, thereby cross-validating the results (Supplementary Figure 13A 
& B). The tumor-specific fluorescence attenuation was then used to estimate the 
concentration of B8-FITC in tumors isolated from B8-FITC-treated mice, which was 
established to be 26.4 ± 10.5 M, a concentration that is well above the IC50.  
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Taken together these data are consistent with a direct inhibitory activity of vascin on 
VEGFR2 function in vivo in the same manner that was observed in cells. 
 
Amyloid toxicity is conditional to VEGFR2 dependence of cells 
We determined loss of VEGFR2 function and vascin amyloid toxicity in several 
cell lines. CellTiter Blue cytotoxicity assays (Figure 4B) revealed that in HUVECs loss 
of function of the receptor (IC50 of 6.8 +- 0.5 M for receptor autophosphorylation 
and 8.3 +- 0.4 M for ERK phosphorylation) goes hand in hand with cytotoxicity. On 
the other hand in HEK293 or U2OS cells neither 2.5-100 M of vascin or its 
scrambled counterpart were found to be toxic to either (Figure 4C and D). Upon 
transfection of VEGFR2 in HEK293 we observed that, after VEGF stimulation, ERK 
phosphorylation was inhibited upon treatment with 20 M vascin (Supplementary 
figure 14A) which induced the aggregation of the VEGFR2 as evidenced on the 
fractionation assay (Supplementary figure 14B). However, no noticeable toxicity of 
vascin to HEK293 cells was observed in the range of 2.5 - 100 M (Figure 4E). This 
demonstrates that vascin is not toxic to HEK293 cells in the absence of VEGFR2 but 
also that aggregation of transiently expressed VEGFR2 in these lines does not affect 
cell viability. Similar observations were made with U2OS cells transfected with 
VEGFR2 (Figure 4F). Thus vascin does not display generic amyloid toxicity and the 
aggregation of VEGFR2 by vascin is in itself also not toxic. Finally, as neurons are 
thought to be particularly sensitive to aggregate toxicity we also compared them 
with primary cortical neurons, which do not express VEGFR2. Although with these 
neurons we observed significant toxicity upon peptide treatment (Figure 4G), 
CellTiter Blue reaction levels were similar for the vascin and its scrambled non-
amyloid variant, suggesting that the toxicity was not amyloid-specific but rather 
reflects the high sensitivity of these cultures, which also resulted in a large variability 
in the assay. To control for this we turned to human iPSCs differentiated to a cortical 
neuronal phenotype, which was verified using q-RT-PCR for genes specific for this 
cell type (Supplementary Figure 15). In these cultures we observed a lack of amyloid-
specific toxicity, although there is 10% toxicity associated with administration of 
both vascin and the scrambled peptide. 
 Together these data suggest that amyloid toxicity is not dependent on cell 
type or even on target protein aggregation but that amyloid toxicity is mainly 
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determined by the biological context in which the target protein is inactivated by 
aggregation. As HUVEC survival is dependent on VEFGR2 function, its molecular loss 
of function by aggregation translates in gain of toxic phenotype. 
 
DISCUSSION 
About thirty amyloidogenic proteins are known to contribute to human disease. 
These diseases include neurodegenerative diseases such as Alzheimer’s or 
Parkinson’s disease but also organ-specific and systemic amyloidosis such as 
diabetes mellitus type-2 or light chain amyloidosis(7). Although the 
pathophysiological profiles of these diseases are disparate, involving the aggregation 
of different proteins, affecting distinctive cell types or tissues and having very 
different progression rates, they also share common structural, biochemical and 
biological features suggesting that amyloids might also have similar modes of 
interaction with cellular components(8). Although amyloids of different proteins 
have been shown to interact with lipids(40), proteins(41) and nucleic acids(42), it is 
currently unclear which of these interactions are relevant for disease. While some 
amyloid interactions are rather unspecific, e.g. with biological lipids(43) other 
amyloid interactions are highly specific(20). The most prominent of these is the self-
interaction of amyloidogenic sequences during amyloid fibril formation which 
includes both amyloid nucleation and fiber elongation(44, 45). Proteome wide 
studies using amyloid prediction algorithms suggest that most proteins possess 
amyloidogenic sequence segments within their structure even though they do not 
form amyloid under normal conditions(5, 6). Given the sequence specificity of 
amyloid seeding this suggests that amyloid aggregation should be specifically 
inducible in non-amyloid associated proteins by exposing them to amyloid seeds 
consisting of amyloidogenic peptides derived from their own sequence. 
 
Here we demonstrate that aggregation of endogenously expressed VEGFR2 
can be induced under physiological conditions by exposing it to vascin, a peptide 
consisting of a tandem repeat of an amyloidogenic sequence in its signal peptide. We 
find that vascin possesses all attributes of natural amyloids including cross-beta 
structure, the population of amyloid precursor aggregates, and the ability to reach 
the cytoplasmic compartment of cells, confirming that the signal peptide of VEGFR2 
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possesses a genuine amyloidogenic sequence. In addition we find that vascin is able 
to induce VEGFR2 aggregation by direct interaction with VEGFR2. As vascin is 
targeting the VEGFR2 signaling peptide, seeding of VEGFR2 aggregation is likely to 
be co-translational as suggested by ribosomal colocalization of vascin in the 
cytoplasm and the occurrence of partial VEGFR2 degradation along with its 
aggregation. This results in VEGFR2 inactivation in vitro but also in vivo where it 
inhibits VEGFR2 dependent tumor growth upon intravascular administration. Both 
the aggregation as well as the inhibition of VEGFR2 is specific. Indeed, scrambled 
vascin does not interact with VEGFR2, nor does it provoke VEGFR2 aggregation or 
inhibition. In addition, whereas vascin suppresses cell surface presentation of VEFR2, 
it does not affect trafficking of other receptors such as CD29. Finally, vascin-induced 
VEGFR2 aggregation is not inherently toxic as it does not affect the viability of 
VEGFR2 overexpressing HEK293 cells. Together these findings show that VEGFR2, a 
protein not associated with amyloid disease, can be specifically induced to aggregate 
in the presence of specific amyloid seeds that are derived from its own sequence. 
There may be multiple reasons why large scale amyloidosis is not observed under 
natural conditions despite the likely prevalence of potentially amyloidogenic 
sequences in many proteins. First, most amyloidogenic sequences are buried in 
globular protein domains, which is probably the main protective factor against 
amyloidosis(46). Moreover, most misfolded proteins will be actively degraded in the 
cell before they have the opportunity to aggregate(47). Secondly, even in unfolded or 
intrinsically disordered proteins most amyloidogenic sequences are generally still 
sufficiently protected from aggregation by structural mechanisms such as 
gatekeeping(48) (i.e. the inhibition of aggregation by charged residues adjacent to 
the amyloidogenic segment) and entropic bristles(49) (i.e. unstructured protein 
segments that entropically prevent the association of amyloidogenic sequences). 
Finally interaction with molecular chaperones will also contribute to the inhibition of 
aggregation(50). The reason why vascin can overcome these potential protective 
mechanisms is not yet clear but might reside in its design:  Vascin comprises a 
tandem repeat of an amyloidogenic sequence, which exacerbates the aggregation 
propensity of this sequence and leads to the formation of soluble and stable 
oligomeric aggregates, and these are likely to provide efficient sites for seeding. 
Incidentally, yeast prions often consist of peptide sequence repeats(32) and the 
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stability of soluble oligomers consisting of tandem peptide repeats recently allowed 
their structure solvation by X-ray crystallography(29).  
The toxic gain-of-function observed in many amyloid-associated diseases 
remains poorly explained. This is mainly due to the impossibility to relate loss-of-
function effects to the aggregation process of a given protein. Indeed for many 
amyloid proteins, especially in neurodegeneration, the functional role of the affected 
protein is often complex and not entirely understood(25, 26), which makes it difficult 
to unequivocally identify loss-of-function effects. In addition the interactions of 
amyloid with cellular components in disease is also not clarified so that again gain-
of-toxic function is not directly tractable at the molecular level. The availability of our 
artificial amyloid model provides an opportunity to study the relationship between 
amyloid toxicity and specific protein loss-of-function. Indeed while recapitulating 
essential amyloid features our model also allows to monitor the effect of amyloidosis 
on a functionally well-characterized protein. Moreover, the use of a VEGFR2 
fragment allows assessing amyloid toxicity independently of VEGFR2 function.  
Our results demonstrate that using this setup vascin does not display generic 
toxic properties but rather to the contrary. Vascin gain-of-function is specific (i.e. it is 
dependent on the presence of VEGFR2) but also conditional (i.e. VEGFR2 needs to be 
expressed in the cell but the cell also needs to be dependent on VEGFR2 for its 
survival/proliferation). Indeed in VEGFR2 dependent HUVECs vascin toxicity and 
VEGFR2 loss-of-function correlate in a dose-responsive manner whereas this is not 
the case in VEGFR2 expressing HEK293 cells. Together these results therefore 
illustrate how amyloid toxicity can result from a conjunction of protein specific and 
cell dependent protein loss-of-function.  
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Figure Legends 
 
Figure 1 – Biophysical characterization of the amyloids formed by vascin. (A-D) 
Transmission Electron Microscopy image of 300 M vascin in 1% (w/v) NH4CO3 after 
24h incubation at room temperature and negatively stained with 2% (w/v) uranyl 
acetate. (E) Tinctorial analysis of fibrils of 40 M vascin in 1% (w/v) NH4CO3 after 
18h incubation at room temperature. (F) Fiber x-ray diffraction pattern of fibrils 
formed in 300 M vascin in 1% (w/v) NH4CO3. (G) ESI–IMS–MS Driftscope plot of the 
vascin monomer (1) through to the heptamer (7) present two minutes after diluting 
the monomer to a final peptide concentration of 100 μM in in 1% (w/v) NH4CO3. ESI–
IMS–MS Driftscope plots show the IMS drift time versus mass/charge (m/z) versus 
intensity (z, square-root scale). (H) Histogram of size distribution of particles 
calculated from the DLS data recorded during vascin aggregation. using a linear 
polymer as particle model. (E) Fourier Transform Infrared Spectrum (FTIR) of 300 
M vascin in 1% (w/v) NH4CO3 at t= 5 min (red) and t=24h (blue). (J) Time 
progression of the intensity of the absorbtion peak in the FTIR spectrum in panel E 
around 1628 cm-1. 
 
Figure 2 – Vascin directly interacts with VEGFR2 in cells (A) Cellular distribution 
of carboxyfluorescein-labeled vascinK11 (CF-vascinK11) (green) at 1 M in HUVEC cells. 
(B) Overlay between the fluorescence of CF-vascinK11 (2,5 M green) and the 
amyloid specific dye pFTAA (5 M, red). Overlap is shown as yellow colouring. (C) 
Equivalent image as B for the Proline mutant of vascin. (D) HUVEC cells treated for 4 
hours with CF-vascinK11 (green) at 2.5 M and co-immunostained for the ER-specific 
marker calnexin (red). (E) HUVEC cells treated for 4 hours with CF-vascinK11 at 5.0 
M (green) and co-immunostained for the ribosomal protein S6 (red). (F) Proximity 
ligation (Duo-Link) between CF-vascinK11 at 5 M and VEGFR2 performed in HUVEC 
cells treated for 4 hours with peptide. For panels A, D, E and F the nuclei are stained 
with DAPI in blue. (G) Quantification of the Duo-Link signal by high content 
microscopy of HUVEC cells treated with vascin as depicted in (E). For each condition 
about 1000 cells were analyzed and the average fluorescence intensity per cell is 
shown. (H) dSTORM image of HUVEC cells treated for 4 hours with 0.5 M Alexa647 
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labeled vascinK11 (purple) and co-immunostained for VEGFR2 (green). Scale bar is 1 
m. (I) Magnification of image in G where arrowheads indicate the interaction of 
vascin and VEGFR2. Scale bar is 1 m.  
 
Figure 3 – Vascin knocks down VEGFR2 activity. (A) Western blot analysis for 
VEGFR2 co-immunoprecipitation in HUVEC cells treated for 4 hours with 20 M 
biotin-PEG labeled vascin. (B) Western blot analysis of the partitioning of VEGFR2 
between the soluble and insoluble fraction of HUVEC cells treated with 20 M vascin. 
(C) Western blot analysis of the SDS-gradient extraction of the soluble and insoluble 
fraction of HUVEC cells treated with 20 M vascin. (D) Dose-response curve of the 
effect of 2.5-100 M vascin on VEGF stimulation of VEGFR2 autophosphorylation in 
HUVEC cells. (E) Dose-response curve of the effect of 2.5-100 M vascin on VEGF 
stimulation of ERK phosphorylation in HUVEC cells. (F) VEGFR2 
autophosphorylation and ERK phosphorylation in HUVEC cells treat with 20 M 
vascin, human vascin (h.vascin), scrambled vascin and proline mutant vascin (Pro). 
(G) Quantification by Fluorescence Activated Cell Sorting (FACS) of the fraction of 
cells that display VEGFR2 and CD29 on the cell surface upon treatment with vascin or 
scrambled vascin at 20 M. (H) Quantification of ERK phosphorylation level as 
determined by MSD assay upon EGF stimulation of Hela cells treated with 20 M 
vascin or its scrambled version. (I) Lag phase of the aggregation kinetics of the 
Alzheimer -peptide 1-40 observed with Thioflavin T fluorescence in the presence of 
1% molar fraction of homotypic seeds, or the equivalent amount of seeds of vascin, 
human vascin, scrambled vascin or the proline mutant vascin. (J) Equivalent 
experiment to panel I for the human Prion protein (PrP). 
 
Figure 4 – In vivo effect of Vascin and cell-type dependent cytotoxicity. (A) 
Tumor growth curves of subcutaneously inject B6 melanoma cells in C57BL6 mice 
treated with daily intravenous injections of 10 mg/kg vascin or its scramble. As a 
positive control we used the inhibitor of the VEGFR2 tyrosine kinase activity 
PTK787. (B-H) Dose dependent toxicity of vascin or its scrambled version tested 
from 2.5 M – 100 M by the CellTiter Blue assay on (B) HUVEC cells. (C) HEK293 
cells. (D) U2OS cells. (E) HEK293 cells transiently overexpressing VEGFR2. (F) U2OS 
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cells transiently overexpressing VEGFR2. (G) Cortical primary neuron cells from 
mouse and induced pluripotent stem cells (iPSCs) after a neuronal differentiation 
protocol. 
